A recent whitepaper by Bruce Pyenson and Milliman colleagues suggests the Institute for Clinical and Economic Review’s (ICER) cost-effectiveness analyses offer little benefit in payers’ drug coverage decisions.
According to a Catalyst report, the following are some issues raised in the white paper:
- ICER models are not flexible to payers’ customization needs;
- The quality-adjusted life year has “limited practical use in real-world decision making”; and
- ICER prefers randomized controlled trials data over RWE.